U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation

Koji Haratani(Dana-Farber Cancer Institute), Kazuhiko Nakagawa(Osaka Red Cross Hospital)

Journal of Clinical Investigation

October 29, 2019

10.1172/jci126598

Cited by 81

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

|New England Journal of Medicine|2014|3.2k

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

|Journal of Clinical Oncology|2011|1.6k

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2017|1.2k

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

|JAMA Oncology|2017|1k